Phase I Study of BCMA CAR-T using instant manufacturing platform or traditional production process for relapsed/refractory multiple myeloma therapy

被引：0
|
作者：
Liu, Hui [1 ]
Wang, Ting [1 ]
Yang, Yazi [1 ]
Feng, Ru [1 ]
Li, Jiangtao [1 ]
Zhang, Chunli [1 ]
Bai, Jiefei [1 ]
Ding, Yanping [2 ]
Liu, Guanghua [2 ]
Wu, Fei [2 ]
Lu, Xinan [2 ]
He, Ting [2 ]
机构：
[1] Beijing Hosp, Beijing, Peoples R China
[2] Beijing Imunopharm Technol Co Ltd, Beijing, Peoples R China
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA-07
引用
收藏
页码：S5 / S5
页数：1
相关论文
共 50 条
  • [21] Anti-BCMA CAR-T Cell Therapy in Relapsed or Refractory Multiple Myeloma Patients with Impaired Renal Function
    Shao-long He
    Yu-hang Cheng
    Di Wang
    Meng-lei Xu
    Yi-mei Que
    Yan-jie Xu
    Liang-ming Ma
    Chun-rui Li
    Jian-feng Zhou
    Current Medical Science, 2021, 41 : 474 - 481
  • [22] Sequential Administration of Selinexor and CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma
    Gill, Sarvarinder Kaur
    Biran, Noa
    Phull, Pooja
    Vesole, David H.
    Siegel, David S.
    Parmar, Harsh
    BLOOD, 2023, 142
  • [23] CAR-T cell therapy in relapsed or refractory multiple myeloma and access in Turkey
    Hakan, Goker
    Engin, Kelkitli
    Elifcan, Karakulak Aladag
    Haluk, Demiroglu
    Mehmet, Turgut
    Suman, Kambhampati
    Maxwell, Krem
    FRONTIERS IN MEDICINE, 2024, 11
  • [24] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Wang, Qingming
    Wei, Runhong
    Guo, Shufang
    Min, Chao
    Zhong, Xiong
    Huang, Hui
    Cheng, Zhi
    CANCER GENE THERAPY, 2024, 31 (01) : 108 - 118
  • [25] Remission observed from a phase 1 clinical study of CAR-T therapy with safety switch targeting BCMA for patients with relapsed/refractory multiple myeloma.
    Liu, Yarong
    Chen, Zhi
    Wei, Runhong
    Shi, Lin
    He, Feng
    Shi, Zixiao
    Jin, Tao
    Xie, Ronglin
    Wei, Baofeng
    Chen, Jing
    Fang, Hongliang
    Zhu, Bo
    Li, Qi-Jing
    Wang, Pin
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [26] An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
    Qingming Wang
    Runhong Wei
    Shufang Guo
    Chao Min
    Xiong Zhong
    Hui Huang
    Zhi Cheng
    Cancer Gene Therapy, 2024, 31 : 420 - 426
  • [27] Phase I Study of PHE885, a Fully Human BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <2 Days Using the T-Charge TM Platform
    Sperling, Adam S.
    Nikiforow, Sarah
    Nadeem, Omar
    Mo, Clifton C.
    Laubach, Jacob P.
    Anderson, Kenneth C.
    Alonso, Alejandro
    Ikegawa, Shuntaro
    Prabhala, Rao
    Rodriguez, Diego Hernandez
    Daley, Heather
    Shaw, Kit L.
    Arihara, Yohei
    Ansari, Soudeh
    Quinn, David S.
    Pearson, David
    Hack, Anniesha
    Treanor, Louise M.
    Bu, Dexiu
    Mataraza, Jennifer
    Rispoli, Lawrence
    Credi, Marc
    Ritz, Jerome
    De Vita, Serena
    Munshi, Nikhil C.
    BLOOD, 2021, 138 : 3864 - +
  • [28] Cilta-cel, a BCMA-targeting CAR-T therapy for heavily pretreated patients with relapsed/refractory multiple myeloma
    Martin, Thomas G.
    Madduri, Deepu
    Pacaud, Lida
    Usmani, Saad Z.
    FUTURE ONCOLOGY, 2023, 19 (34) : 2297 - 2311
  • [29] Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
    Jin, Chunxiang
    Chen, Rongrong
    Fu, Shan
    Zhang, Mingming
    Teng, Yuanyin
    Yang, Tingting
    Song, Fengmei
    Feng, Jingjing
    Hong, Ruimin
    Cui, Jiazhen
    Huang, Simao
    Xu, Huijun
    Zhang, Yanlei
    Wei, Guoqing
    Cai, Zhen
    Kwong, Yok-Lam
    Chan, Thomas Sau Yan
    Chang, Alex H.
    Huang, He
    Hu, Yongxian
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2025, 13 (03)
  • [30] Phase II Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/ Refractory Multiple Myeloma
    Chen, Wenming
    Fu, Chengcheng
    Fang, Baijun
    Liang, Aibin
    Xia, Zhongjun
    He, Yanjuan
    Lu, Jin
    Liu, Hui
    Hou, Ming
    Cai, Zhen
    Yang, Wei
    Hao, Siguo
    Jiang, Songfu
    Jing, Hongmei
    Liu, Jing
    Du, Xin
    Fu, Rong
    Mei, Heng
    Zhu, Zunmin
    Yang, Yanli
    Liu, Hong
    Yuan, Daijing
    Zhao, Hongxia
    Xiao, Jun
    Wang, Wei
    Wang, Huamao
    Li, Zonghai
    BLOOD, 2022, 140 : 4564 - 4565
12345